Low-Dose Metronomic Paclitaxel Chemotherapy Suppresses Breast Tumors and Metastases in Mice

REFERENCES

• Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55, 74–108.
   PubMed Web of Science ®Google Scholar
• Demichell, R.; Valagussa, P.; Bonadonna, G. Does surgery modify growth kinetics of breast cancer micrometastases. Br J Cancer 2001, 85, 490–492.
   PubMed Web of Science ®Google Scholar
• Hansen, E.; Wolff, N.; Knuechel, R.; Ruschoff, J.; Hofstaedter, F.; Taeger, K. Tumour cells in bloodshed from the surgical field. Arch Surg 1995, 130, 387–393.
   PubMedGoogle Scholar
• Clemons, M.; Goss, P. Estrogen and the risk of breast cancer. N Engl J Med 2001, 344, 276–285.
   PubMed Web of Science ®Google Scholar
• Miller, W.R. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003, 30, 3–11.
   PubMed Web of Science ®Google Scholar
• Arbuck, S.G.; Dorr, A.; Friedman, M.A. Paclitaxel (Taxol) in breast cancer. Hematol Oncol Clin North Am 1994, 8, 121–140.
   PubMed Web of Science ®Google Scholar
• Horwitz, S.B.; Cohen, D.; Rao, S.; Ringel, I.; Shen, H.J.; Yang, C.P. Paclitaxel: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993, 15, 55–61.
   PubMedGoogle Scholar
• Weisis, R.B.; Donehower, R.C.; Wiernik, P.H.; Ohnuma, T.; Gralla, R.J.; Trump, D.L., Hypersensitivity reactions from paclitaxel. J Clinl Oncol 1990, 8, 1263–1268.
   PubMed Web of Science ®Google Scholar
• Lennernäs, B.; Albertsson, P.; Damber, J.E.; Norrby, K. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study. APMIS 2004, 112, 201–209.
   PubMed Web of Science ®Google Scholar
• Bocci, G.; Nicolaou, K.C.; Kerbel, R.S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002, 62, 6938–6943.
   PubMed Web of Science ®Google Scholar
• Ng, S.S.; Sparreboom, A.; Shaked, Y.; Lee, C.; Man, S.; Desai, N., Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res 2006, 12, 4331–4338.
   PubMed Web of Science ®Google Scholar
• Drevs, J.; Fakler, J.; Eisele, S.; Medinger, M.; Bing, G.; Esser, N., Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004, 24, 1759–1763.
   PubMed Web of Science ®Google Scholar
• Klement, G.; Huang, P.; Mayer, B.; Green, S.K.; Man, S.; Bohlen, P., Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002, 8, 221–232.
   PubMed Web of Science ®Google Scholar
• Radice, D.; Redaelli, A. Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics 2003, 21, 383–396.
   PubMed Web of Science ®Google Scholar
• Pulaski, B.A.; Ostrand-Rosenberg, S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998, 58, 1486–1493.
   PubMed Web of Science ®Google Scholar
• Aslakson, C.J.; Miller, F.R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992, 52, 1399–1405.
   PubMed Web of Science ®Google Scholar
• Kanwar, J.R.; Palmano, K.P.; Sun, X.; Haggarty, N.; Kanwar, R.K.; Gupta, R., “Iron-saturated” lactoferrin exhibits significantly greater anti-tumour activity than natural lactoferrin in combination with cancer chemotherapy. Cancer Immunol Immunother 2008, 86, 277–288.
   Google Scholar
• Kuwabara, T.; Cogan, D.G. Studies of retinal vascular patterns: Part I normal architecture. Arch Ophthalmol 1960, 64, 904–911.
   PubMed Web of Science ®Google Scholar
• Sun, X.; Qiao, H.; Jiang, H.; Zhi, X.; Liu, F.; Wang, J., Intramuscular delivery of anti-angiogenic genes suppresses secondary metastases after removal of primary tumors. Cancer Gene Ther 2005, 12, 35–45.
   PubMed Web of Science ®Google Scholar
• Ma, L.; Luo, L.; Qiao, H.; Dong, X.; Pan, S.; Jiang, H., Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol 2006, 46, 98–106.
   PubMed Web of Science ®Google Scholar
• Liu, F.; Wang, P.; Jiang, X.; Tan, G.; Qiao, H.; Jiang, H., Antisense hypoxia-inducible factor 1 α gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinomas. Cancer Sci 2008, 99, 2055–2061.
   PubMed Web of Science ®Google Scholar
• Melichar, B.; Dvorak, J.; Hyspler, R.; Zadak, Z. Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents. Chemotherapy 2005, 51, 336–338.
   PubMed Web of Science ®Google Scholar
• Cunnick, G.H.; Jiang, W.G.; Gomez, K.F.; Mansel, R.E. Lymphangiogenesis and breast cancer metastasis. Histol Histopathol 2002, 17, 863–870.
   PubMed Web of Science ®Google Scholar
• Takahashi, Y.; Mai, M.; Sawabu, N.; Nishioka, K. A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer. Pancreas 2005, 30, 206–210.
   PubMed Web of Science ®Google Scholar
• Bocci, G.; Francia, G.; Man, S.; Lawler, J.; Kerbel, R.S. Thrombospondin 1, amediator of the antiangiogenic effects of low-dose metronomicchemotherapy. Proc Natl Acad Sci USA 2003, 100, 12917–12922.
   PubMed Web of Science ®Google Scholar
• Bell, K.A.; Perna, A.G.; Hsu, S. Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer. J Am Acad Dermatol 2001, 45, 790.
   PubMed Web of Science ®Google Scholar
• Ogawa, Y.; Ishikawa, T.; Chung, S.H.; Ikeda, K.; Takashima, T.; Onoda, N., Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer. Anticancer Res 2003, 23, 3453–3457.
   PubMed Web of Science ®Google Scholar
• Wang, J.; Lou, P.; Lesniewski, R.; Henkin, J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003, 14, 13–19.
   PubMed Web of Science ®Google Scholar
• Bertolini, F.; Paul, S.; Mancuso, P.; Monestiroli, S.; Gobbi, A.; Shaked, Y., Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003, 63, 4342–4346.
   PubMed Web of Science ®Google Scholar
• Kabrun, N.; Buhring, H.J.; Choi, K.; Ullrich, A.; Risau, W.; Keller, G. Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 1997, 124, 2039–2048.
   PubMed Web of Science ®Google Scholar
• Shibuya, M.; Claesson-Welsh, L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006, 12, 549–560.
   Google Scholar
• Joukov, V.; Pajusola, K.; Kaipainen, A.; Chilov, D.; Lahtinen, I.; Kukk, E., A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996, 15, 290–298.
   PubMed Web of Science ®Google Scholar
• Dawson, D.W.; Pearce, S.F.; Zhong, R.; Silverstein, R.L.; Frazier, W.A.; Bouck, N.P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997, 138, 707–717.
   PubMed Web of Science ®Google Scholar
• Damber, J.E.; Vallbo, C.; Albertsson, P.; Lennernas, B.; Norrby, K. The antitumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 2006, 58, 354–360.
   PubMed Web of Science ®Google Scholar
• Hamano, Y.; Sugimoto, H.; Soubasakos, M.A.; Kieran, M.; Olsen, B.R.; Lawler, J., Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004, 64, 1570–1574.
   PubMed Web of Science ®Google Scholar
• Munoz, R.; Shaked, Y.; Bertolini, F.; Emmenegger, U.; Man, S.; Kerbel, R.S. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005, 14, 466–479.
   PubMed Web of Science ®Google Scholar
• Widakowich, C.; Dinh, P.; de Azambuja, E.; Awada, A.; Piccart-Gebhart, M. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? Anticancer Agents Med Chem 2008, 8, 488–496.
   PubMed Web of Science ®Google Scholar
• Izumi, Y.; Xu, L.; di Tomaso, E.; Fukumura, D.; Jain, R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416, 279–280.
   PubMed Web of Science ®Google Scholar
• Orlando, L.; Cardillo, A.; Ghisini, R.; Rocca, A.; Balduzzi, A.; Torrisi, R., Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006, 6, 225–232.
   PubMed Web of Science ®Google Scholar
• Dellapasqua, S.; Bertolini, F.; Bagnardi, V.; Campagnoli, E.; Scarano, E., Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008, 26, 4899–4905.
   PubMed Web of Science ®Google Scholar
• Peltier, S.; Oger, J.M.; Lagarce, F.; Couet, W.; Benoît, J.P. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 2006, 23, 1243–50.
   PubMed Web of Science ®Google Scholar
• Bröker, L.E.; Valdivieso, M.; Pilat, M.J.; Deluca, P.; Zhou, X.; Parker, S., Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183. Clin Cancer Res 2008, 14, 4186–4191.
   PubMed Web of Science ®Google Scholar
• Chu, Z.; Chen, J.S.; Liau, C.T.; Wang, H.M.; Lin, Y.C.; Yang, M.H., Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anticancer Drugs 2008, 19, 275–281.
   PubMed Web of Science ®Google Scholar